Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. interventional cardiologist
Show results for
Products
Services

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Interventional Cardiologist Articles & Analysis

30 news found

1st Successful Heart Tumor Removal Without Open Heart Surgery

1st Successful Heart Tumor Removal Without Open Heart Surgery

A cardiac puzzle This procedure, like the one before it, was conducted with the assistance of Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, and EchoPixel’s chief medical officer. ...

ByEchoPixel, Inc.


Shockwave Medical Initiates All-Female Coronary IVL Study

Shockwave Medical Initiates All-Female Coronary IVL Study

EMPOWER CAD is the First Prospective, Female-Only Study of Coronary Interventions Study Seeks to Confirm Benefits of Shockwave’s Coronary IVL in Females Who Historically Have Suffered Less Favorable Clinical Outcomes than Male Patients with Traditional Therapies Shockwave Medical, Inc. ...

ByShockwave Medical Inc.


Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

Inari Medical Announces Results from the Fully Enrolled 800-patient US Cohort of the FlowTriever FLASH Registry

The data was presented during a Late-Breaking Clinical Trial session at the 2022 TCT (Transcatheter Cardiovascular Therapeutics) conference on September 18th by Principal Investigator (PI), Catalin Toma, MD, an Interventional Cardiologist at University of Pittsburgh Medical Center (UPMC). The data was also simultaneously published in EuroIntervention, the ...

ByInari Medical


Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

Puzzle Medical Announces the Successful Completion of its First-in-Human Study with its ModulHeart

Four patients had ModulHeart deployed to provide circulatory support while undergoing high-risk percutaneous coronary intervention (PCI) procedures. All patients experienced improvements in cardiac and kidney function. ...

ByPuzzle Medical Devices Inc.


reSept ASD Occluder implanted in EU for the first time

reSept ASD Occluder implanted in EU for the first time

Professor Jean-Benoît Thambo, head of the department of pediatric and congenital cardiology at the Bordeaux University Hospital, said to France3 how “these prostheses are the first phase of the medicine of tomorrow, a medicine that opts for material adapted to the body, biological”. As interventional cardiologist Zakaria Jalal explained to ...

ByatHeart Medical


Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

Shockwave IVL Coronary Studies Demonstrate Excellent PCI Outcomes in Both Women and Men at One Year

The one-year results from the Disrupt CAD clinical program were presented at the 2022 Scientific Sessions of the Society for Cardiovascular Angiography & Interventions (SCAI). Unlike previous reports with atherectomy that have shown worse angiographic complications in women versus men,i a pooled analysis of the Disrupt CAD III & IV studies showed that IVL was equally ...

ByShockwave Medical Inc.


Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

Robocath achieves positive results in R-Evolution multicenter European clinical study on robotic coronary angioplasty

The study, which included 62 patients across six European centers, shows that coronary angioplasties using the R-One™ robot are safe and effective for patients, while also improving the working conditions for the interventional cardiologist by drastically reducing exposure to X-rays. The results will be presented in detail at a second dedicated session ...

ByRobocath


Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

Saranas® Expands Intellectual Property with Key Patent Integrating Bleed Monitoring and Vascular Access Closure Device

” “From vessel injury to failure of obtaining hemostasis with access closure devices, bleeding complications in interventional procedures continue to pose challenges for clinicians,” said Dr. ...

BySaranas, Inc.


Anteris reports successful interim results for the first-in-human trial for DurAVR

Anteris reports successful interim results for the first-in-human trial for DurAVR

The system also allowed for excellent commissural alignment; a significant patient benefit if future coronary intervention were required. A 20% increase from baseline in 6 min walk test (a measure of patient exercise tolerance). ...

ByAnteris Technologies Limited


Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

Robocath concludes first European clinical study to demonstrate safety and efficacy of robotic coronary angioplasty performed with R-One

Full results of the study are due in May 2022 and will be presented at the EuroPCR conference. Prof. Eric Durand, interventional cardiologist at the Rouen University Hospital center and joint principal investigator for the study, explained: “I feel honored to have had the chance to be joint principal investigator of the R-Evolution clinical study. ...

ByRobocath


Robocath successfully completes first robotic coronary angioplasty with R-One in China

Robocath successfully completes first robotic coronary angioplasty with R-One in China

The procedure took place at the 301 Hospital in Beijing on November 24; performed by Dr. Yundai Chen, a renowned interventional cardiologist and author of several scientific publications. ...

ByRobocath


BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

BioCardia Announces First Patient Treated in CardiAMP Cell Therapy Trial for Chronic Myocardial Ischemia

The first patient was treated with the investigational CardiAMP autologous cell therapy at the University of Wisconsin in Madison, by Interventional Cardiologist and Associate Professor of Medicine Amish Raval, M.D., supported by Peiman Hematti, M.D., Bone Marrow Transplantation Hematologist and Professor of Medicine. ...

ByBiocardia, Inc.


CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

CytoSorbents Receives Full FDA Investigational Device Exemption (IDE) Approval to Begin U.S. STAR-D Trial on Apixaban and Rivaroxaban Removal by the DrugSorb-ATR Antithrombotic Removal System During Urgent Cardiothoracic Surgery

Michael Gibson and an Executive Committee comprised of world–renowned cardiac surgeons, interventional cardiologists, and thrombosis/hemostasis experts. Trial start-up activities are underway and we expect the study to start in the first quarter of ...

ByCytoSorbents Corporation


World’s First Watchman ProcedurewWithout the Use of Contrast Dye

World’s First Watchman ProcedurewWithout the Use of Contrast Dye

Rather than relying on contrast dye and X-ray based imaging to help guide the implant placement, Jacob Dutcher, MD, an interventional cardiologist and director of the Structural Heart Program at CentraCare Heart & Vascular Center, performed the procedure using ultrasound-based 4D holographic imaging, which provides an image so clear that potentially harmful ...

ByEchoPixel, Inc.


Anteris appoints Chief Medical Officer

Anteris appoints Chief Medical Officer

Anteris Technologies Ltd (ASX: AVR) (Anteris or the Company) announces the appointment of the internationally recognized Interventional Cardiologist, Dr Chris Meduri MD MPH, as its Chief Medical Officer (CMO). ...

ByAnteris Technologies Limited


Cardiac Dimensions Announces Launch of Its Optimized U.S. Pivotal Trial - The EMPOWER Trial

Cardiac Dimensions Announces Launch of Its Optimized U.S. Pivotal Trial - The EMPOWER Trial

“I am very excited to launch The EMPOWER Trial,” said Samir Kapadia, M.D., interventional cardiologist, professor of medicine and chairman of the Department of Cardiovascular Medicine at Cleveland Clinic, and the national principal investigator of The EMPOWER Trial. “This will be the first time where we are able to study early ...

ByCardiac Dimensions, Inc.


InspireMD Announces Strong Second Quarter 2021 Financial Results

InspireMD Announces Strong Second Quarter 2021 Financial Results

Christopher Metzger Transferred the listing of the company’s common stock and warrants to the Nasdaq Capital Market for access to broader and more fundamental investor base Appointed seasoned marketing executive Kathryn Arnold to the company’s Board of Directors Appointed acclaimed interventional cardiologist Kenneth Rosenfield, M.D. as Chair of ...

ByInspireMD Inc.


BIOMODEX Technology Enables New Milestone in Interventional Cardiology

BIOMODEX Technology Enables New Milestone in Interventional Cardiology

This breakthrough was achieved by Dr. Reda Ibrahim (interventional cardiologist), Dr. Blandine Mondesert (electrophysiologist), and Dr. ...

ByBIOMODEX


Robocath successfully completes first robotic coronary angioplasties in Belgium

Robocath successfully completes first robotic coronary angioplasties in Belgium

R-One is a robotic platform that assists interventional cardiologists in performing coronary angioplasties. This procedure consists in revascularizing the cardiac muscle, by inserting one or more implants (stents) into the arteries that supply it with blood. ...

ByRobocath


Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation

Cardiac Dimensions Announces Two New Meta-Analysis Publications Showing Statistically Significant and Clinically Meaningful Benefits to Heart Failure Patients Suffering from Functional Mitral Regurgitation

These have included rigorous clinical outcome analysis of the landmark REDUCE FMR Trial3 (the first-ever randomized, blinded, sham-controlled study in the transcatheter mitral valve space) results which highlighted a substantially higher number of patients achieved minimum clinically important differences at 12 months as compared to the sham procedure in 6MWT, KCCQ, NYHA class and reduced heart ...

ByCardiac Dimensions, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT